2023 World Conference on Lung Cancer (Posters)-P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study

P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study - PDF(Slides)

Back to course

Pdf Summary

This study aimed to evaluate the impact of Thyroid transcription factor-1 (TTF-1) expression on the efficacy of combined chemoimmunotherapy in patients with advanced lung adenocarcinoma. TTF-1 is a prognostic factor in lung adenocarcinoma and is expressed in 60-70% of cases. The study enrolled patients with advanced or recurrent lung adenocarcinoma who were treated with first-line combined chemoimmunotherapy at 10 institutions in Japan. The primary endpoint was progression-free survival (PFS).<br /><br />The study found that TTF-1 expression was significantly associated with better PFS in patients receiving combined chemoimmunotherapy. Patients with TTF-1-positive tumors had a median PFS of 10.9 months compared to 5.0 months for those with TTF-1-negative tumors. Additionally, the combination of positive TTF-1 expression and PD-L1 expression in tumors was correlated with better PFS. TTF-1 expression was also found to be a significant prognostic factor in determining the clinical outcome of chemoimmunotherapy.<br /><br />The study also analyzed the association between TTF-1 expression and patient characteristics. The analysis revealed that TTF-1 expression was more common in males and in patients who were current or former smokers. It was also associated with higher PD-L1 expression levels.<br /><br />Furthermore, the study evaluated the treatment efficacy of combined chemoimmunotherapy based on the status of TTF-1 expression. It found that TTF-1-negative tumors were associated with a poor prognosis in patients receiving pemetrexed-containing chemoimmunotherapy.<br /><br />In conclusion, this prospective study demonstrated that TTF-1 expression is an independent prognostic factor in determining the clinical outcome of chemoimmunotherapy in lung adenocarcinoma patients. TTF-1 expression was associated with better PFS and treatment response in specific chemotherapy regimens. These findings suggest that TTF-1 expression could be useful in guiding treatment decisions and therapeutic strategies for patients receiving chemoimmunotherapy.

Asset Subtitle

Yuki Katayama

Meta Tag

Speaker Yuki Katayama

Topic Metastatic NSCLC: Immunotherapy - Biomarker

Keywords

Thyroid transcription factor-1

TTF-1 expression

lung adenocarcinoma

chemoimmunotherapy

prognostic factor

progression-free survival

PD-L1 expression

patient characteristics

pemetrexed-containing chemoimmunotherapy

treatment response